TY - JOUR
T1 - Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients
AU - Minniti, Giuseppe
AU - Moroni, Carlo
AU - Jaffrain-Rea, Marie Lise
AU - Esposito, Vincenzo
AU - Santoro, Antonio
AU - Affricano, Cesare
AU - Cantore, Giampaolo
AU - Tamburrano, Guido
AU - Cassone, Rosario
PY - 2001
Y1 - 2001
N2 - OBJECTIVE: Transsphenoidal surgery results in biochemical remission of acromegaly in 45-80% of patients; however, few studies have addressed the impact of transsphenoidal surgery on cardiovascular function in acromegalic patients. The aim of this prospective study was to investigate the effects of postoperative GH/IGF-I normalization on echocardio-graphic parameters and blood pressure (BP) in a series of patients with active acromegaly. DESIGN: An open prospective study. PATIENTS: Thirty newly diagnosed acromegalic patients undergoing transsphenoidal surgery. MEASUREMENTS: Doppler echocardiography and 24-h ambulatory blood pressure monitoring were performed before and 6 months after transsphenoidal surgery. RESULTS: Fifteen patients were considered to be well controlled postoperatively (group A), as defined by normal age-corrected IGF-I levels and glucose-suppressed GH levels less than 2 mU/l, the remaining 15 patients being considered as poorly controlled (group B). In group A, a postoperative decrease of left ventricular mass index was observed (104.4 ± 6.6 vs. 127.1 ± 7.7 g/m2; P <0.001), associated with an improvement of some indices of diastolic function, such as an increase of the early/late transmitral peak flow velocity (P <0.05) and a decrease of isovolumic relaxation time (P <0.01). No significant change was observed in group B. A significant decrease of 24-h systolic BP was also observed in group A (P <0.05) and five of six patients normalized their BP circadian rythm. In contrast, a nonsignificant increase in BP values, with a persistent blunted BP profile where present, was observed in group B. CONCLUSIONS: We conclude that successful transsphenoidal surgery is able to induce a significant improvement in some cardiac parameters and a slight reduction in systolic blood pressure in acromegalic patients.
AB - OBJECTIVE: Transsphenoidal surgery results in biochemical remission of acromegaly in 45-80% of patients; however, few studies have addressed the impact of transsphenoidal surgery on cardiovascular function in acromegalic patients. The aim of this prospective study was to investigate the effects of postoperative GH/IGF-I normalization on echocardio-graphic parameters and blood pressure (BP) in a series of patients with active acromegaly. DESIGN: An open prospective study. PATIENTS: Thirty newly diagnosed acromegalic patients undergoing transsphenoidal surgery. MEASUREMENTS: Doppler echocardiography and 24-h ambulatory blood pressure monitoring were performed before and 6 months after transsphenoidal surgery. RESULTS: Fifteen patients were considered to be well controlled postoperatively (group A), as defined by normal age-corrected IGF-I levels and glucose-suppressed GH levels less than 2 mU/l, the remaining 15 patients being considered as poorly controlled (group B). In group A, a postoperative decrease of left ventricular mass index was observed (104.4 ± 6.6 vs. 127.1 ± 7.7 g/m2; P <0.001), associated with an improvement of some indices of diastolic function, such as an increase of the early/late transmitral peak flow velocity (P <0.05) and a decrease of isovolumic relaxation time (P <0.01). No significant change was observed in group B. A significant decrease of 24-h systolic BP was also observed in group A (P <0.05) and five of six patients normalized their BP circadian rythm. In contrast, a nonsignificant increase in BP values, with a persistent blunted BP profile where present, was observed in group B. CONCLUSIONS: We conclude that successful transsphenoidal surgery is able to induce a significant improvement in some cardiac parameters and a slight reduction in systolic blood pressure in acromegalic patients.
UR - http://www.scopus.com/inward/record.url?scp=0034852751&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034852751&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2265.2001.01343.x
DO - 10.1046/j.1365-2265.2001.01343.x
M3 - Article
C2 - 11589673
AN - SCOPUS:0034852751
SN - 0300-0664
VL - 55
SP - 307
EP - 313
JO - Clinical Endocrinology
JF - Clinical Endocrinology
IS - 3
ER -